Evidence map›Paper›PMID 32107283›Full record

ArticleMolecular & cellular proteomics : MCP2020

Genetic Profile and Functional Proteomics of Anal Squamous Cell Carcinoma: Proposal for a Molecular Classification.

Lucía Trilla-Fuertes, Ismael Ghanem, Angelo Gámez-Pozo, Joan Maurel, Laura G-Pastrián, Marta Mendiola, Cristina Peña, Rocío López-Vacas, Guillermo Prado-Vázquez, Elena López-Camacho and 13 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular & cellular proteomics : MCP, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 5 institutions in 2 countries.

Lucía Trilla-FuertesBiomedica Molecular Medicine SL, C/ Faraday 7, 28049, Madrid, Spain.
Ismael GhanemMedical Oncology Department, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046, Madrid, Spain.
Angelo Gámez-PozoMolecular Oncology & Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM, Hospital Universitario La Paz -IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain.
Joan MaurelMedical Oncology Department, Hospital Clinic of Barcelona, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, University of Barcelona, Carrer de Villarroel 170, 08036, Barcelona, Spain.
Laura G-PastriánPathology Department, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046, Madrid, Spain; Molecular Pathology and Therapeutic Targets Group, Hospital Universitario La Paz-IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain.
Marta MendiolaMolecular Pathology and Therapeutic Targets Group, Hospital Universitario La Paz-IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain; Biomedical Research Networking Center on Oncology-CIBERONC, ISCIII, Av. Monforte de Lemos 5, 28029, Madrid, Spain.
Cristina PeñaPathology Department, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046, Madrid, Spain.
Rocío López-VacasMolecular Oncology & Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM, Hospital Universitario La Paz -IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain.
Guillermo Prado-VázquezBiomedica Molecular Medicine SL, C/ Faraday 7, 28049, Madrid, Spain.
Elena López-CamachoMolecular Oncology & Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM, Hospital Universitario La Paz -IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain.
Andrea Zapater-MorosMolecular Oncology & Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM, Hospital Universitario La Paz -IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain.
Victoria HerediaBiomedical Research Networking Center on Oncology-CIBERONC, ISCIII, Av. Monforte de Lemos 5, 28029, Madrid, Spain; Translational Oncology Lab, Hospital Universitario La Paz -IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain.
Miriam CuatrecasasPathology Department, Hospital Clínic Universitari de Barcelona, Carrer de Villarroel 170, 08036, Barcelona, Spain.
Pilar García-AlfonsoMedical Oncology Department, Hospital General Universitario Gregorio Marañón, /Dr. Esquerdo 46, 28007, Madrid, Spain.
Jaume CapdevilaMedical Oncology Service, Vall Hebron University Hospital. Vall Hebron Institute of Oncology (VHIO), Paseigg de la Vall d'Hebron 119, 08035, Barcelona, Spain.
Carles ConillRadiotherapy Oncology Department, Hospital Clínic Universitari de Barcelona, Carrer de Villarroel 170, 08036, Barcelona, Spain.
Rocío García-CarboneroMedical Oncology Service, Hospital Universitario 12 de Ocubre, Av. de Córdoba s/n, 28041, Madrid, Spain.
Ricardo Ramos-RuizGenomics Unit Cantoblanco, Parque Científico de Madrid, C/ Faraday 7, 28049, Madrid, Spain.
Claudia FortesFunctional Genomics Center Zurich, University of Zurich/ETH Zurich, Winterthurerstrasse 190, CH-8057, Zurich, Switzerland.
Carlos LlorensBiotechvana SL, Parque Científico de Madrid, C/ Faraday 7, 28049, Madrid, Spain.
Paolo NanniFunctional Genomics Center Zurich, University of Zurich/ETH Zurich, Winterthurerstrasse 190, CH-8057, Zurich, Switzerland.
Juan Ángel Fresno VaraMolecular Oncology & Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM, Hospital Universitario La Paz -IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain; Biomedical Research Networking Center on Oncology-CIBERONC, ISCIII, Av. Monforte de Lemos 5, 28029, Madrid, Spain.
Jaime FeliuMedical Oncology Department, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046, Madrid, Spain; Biomedical Research Networking Center on Oncology-CIBERONC, ISCIII, Av. Monforte de Lemos 5, 28029, Madrid, Spain; Cátedra UAM-Amgen, Universidad Autónoma de Madrid, Ciudad Universitaria de Cantoblanco, 28049, Madrid, Spain. Electronic address: jaimefeliu@hotmail.com.
Hospital Universitario La Paz · ESUniversity of Zurich · CHHospital General Universitario Gregorio Marañón · ESUniversitat de Barcelona · ESVall d'Hebron Hospital Universitari · ES

Funding

A Health IT based Psychoeducational Intervention for African American Prostate CancerR01MD007783 · NIMHD · MOREHOUSE SCHOOL OF MEDICINE · PI RIVERS, BRIAN M. · 2014 to 2019
$1.8M
NIMHD NIH HHS R01 MD007783
6 · The paper itself

Abstract

Anal squamous cell carcinoma is a rare tumor. Chemo-radiotherapy yields a 50% 3-year relapse-free survival rate in advanced anal cancer, so improved predictive markers and therapeutic options are needed. High-throughput proteomics and whole-exome sequencing were performed in 46 paraffin samples from anal squamous cell carcinoma patients. Hierarchical clustering was used to establish groups

Indexed as

ProteomicsAdultAgedAged, 80 and overAnus NeoplasmsCarcinoma, Squamous CellCell AdhesionCell ProliferationCohort StudiesExome SequencingFemaleGene Regulatory NetworksHumansLymphocytes, Tumor-InfiltratingMaleMiddle AgedNeoplasm ProteinsProteomeanal squamous cell carcinomabioinformaticscancer biologymass spectrometrymolecular biologymolecular classificationOmicspersonalized medicineproteomicswhole-exome sequencing

Identifiers

PMID32107283
PMCPMC7124473
OpenAlexW3008584258

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.